Sulfated chitosan mitigates acute lung injury induced bone loss via immunoregulation

Abstract

Respiratory inflammatory diseases disrupt bone metabolism and cause pathological bone loss. The lung-bone axis is established in chronic diseases like asthma and cystic fibrosis but is less studied in acute lung injury (ALI), recently implicated in COVID-19-induced bone loss. This study examined the effects of LPS-induced ALI on bone phenotype and explored the role of 2-N, 6-O sulfated chitosan (26SCS) in mitigating pneumonia-induced bone loss via inflammatory response modulation. Our findings show that 26SCS effectively reaches bone tissue after oral administration. It promotes macrophage polarization to the M2 phenotype, alleviating immune cascade reactions and inhibiting osteoclast-mediated bone resorption. Increased M2 macrophages support type H vessel formation, enhancing inflammatory bone vascularization. These effects foster a favorable osteogenic microenvironment and mitigate ALI-induced bone loss. While dexamethasone is effective in reducing inflammation, it can aggravate ALI-induced bone loss. Our research offers a therapeutic strategy targeting the lung-bone axis for inflammation-induced bone loss.

References

[1] Cheng, L. et al. Omicron COVID-19 case estimates based on previous SARS-CoV-2 wastewater load, regional municipality of peel, Ontario, Canada. Emerg. Infect. Dis. 29, 1580 (2023).

[2] Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related?. Clin. Microbiol. Infect., 2020, 26: 729-734

[3] Gupta Aet al.. Extrapulmonary manifestations of COVID-19. Nat. Med, 2020, 26: 1017-1032

[4] Ryu JKet al.. Fibrin drives thromboinflammation and neuropathology in COVID-19. Nature, 2024, 633: 905-913

[5] Fraser, E. Long term respiratory complications of covid-19. BMJ370, m3001 (2020).

[6] Davis HEet al.. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine, 2021, 38 101019

[7] Dusad Aet al.. Organic dust, lipopolysaccharide, and peptidoglycan inhalant exposures result in bone loss/disease. Am. J. Respir. Cell Mol. Biol., 2013, 49: 829-836

[8] Shead EF, Haworth CS, Barker H, Bilton D, Compston JE. Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis. J. Cyst. Fibros., 2010, 9: 93-98

[9] Qiao Wet al.. SARS-CoV-2 infection induces inflammatory bone loss in golden Syrian hamsters. Nat. Commun., 2022, 13 2539

[10] Ma Cet al.. CCL12 induces trabecular bone loss by stimulating RANKL production in BMSCs during acute lung injury. Exp. Mol. Med, 2023, 55: 818-830

[11] Sims NA, Gooi JH. Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption. Semin. Cell Dev. Biol., 2008, 19: 444-451

[12] Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol., 2007, 7: 292-304

[13] Walsh MCet al.. OSTEOIMMUNOLOGY: Interplay between the immune system and bone metabolism. Annu. Rev. Immunol., 2006, 24: 33-63

[14] Dewhirst FE, Stashenko PP, Mole JE, Tsurumachi T. Purification and partial sequence of human osteoclast-activating factor: identity with interleukin 1 beta. J. Immunol., 1985, 135: 2562-2568

[15] Lam Jet al.. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest., 2000, 106: 1481-1488

[16] Asagiri, M. & Takayanagi, H. The molecular understanding of osteoclast differentiation. Bone. 40, 251–264 (2007).

[17] Abu-Amer, Y., Ross, F. P., Edwards, J. & Teitelbaum, S. L. Lipopolysaccharide-stimulated Osteoclastogenesis Is Mediated by Tumor Necrosis Factor Via its P55 Receptor. J. Clin. Invest. 100, 1557–1565 (1997).

[18] Mao D, Epple H, Uthgenannt B, Novack DV, Faccio R. PLCγ2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. J. Clin. Invest., 2006, 116: 2869-2879

[19] Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature, 2003, 423: 349-355

[20] Alkhamees, O. A. Anti-osteoporotic effects of an antidepressant tianeptine on ovariectomized rats. Biomed. Pharmacother.87, 575–582 (2017).

[21] Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat. Rev. Drug Discov., 2012, 11: 234-250

[22] Smolen JSet al.. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann. Rheum. Dis., 2009, 68: 823-827

[23] Mundy GR. Osteoporosis and Inflammation. Nutr. Rev., 2008, 65: S147-S151

[24] Weivoda, M. M. & Bradley, E. W. Macrophages and Bone Remodeling. J. Bone Mineral Res. 38, 359–369 (2023).

[25] Murray PJ. Macrophage Polarization. Annu. Rev. Physiol., 2017, 79: 541-566

[26] Muñoz J, Akhavan NS, Mullins AP, Arjmandi BH. Macrophage polarization and osteoporosis: a review. Nutrients, 2020, 12: 2999

[27] Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature, 2003, 423: 337-342

[28] Champagne, C. M., Takebe, J., Offenbacher, S. & Cooper, L. F. Macrophage Cell Lines Produce Osteoinductive Signals That Include Bone Morphogenetic Protein-2. Bone, 30, 26–31 (2002).

[29] Xiang Zet al.. Dexamethasone suppresses immune evasion by inducing GR/STAT3 mediated downregulation of PD-L1 and IDO1 pathways. Oncogene, 2021, 40: 5002-5012

[30] Lammers Tet al.. 33Dexamethasone nanomedicines for COVID-19. Nat. Nanotechnol., 2020, 15: 622-624

[31] Rhen T, Cidlowski JA. Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs. N. Engl. J. Med., 2005, 353: 1711-1723

[32] Li, X. et al. Excess glucocorticoids inhibit murine bone turnover via modulating the immunometabolism of the skeletal microenvironment. J. Clin. Invest.134, e166795 (2024).

[33] Kusumbe AP, Ramasamy SK, Adams RH. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature, 2014, 507: 323-328

[34] Ramasamy SKet al.. Blood flow controls bone vascular function and osteogenesis. Nat. Commun., 2016, 7 13601

[35] Yu Yet al.. 27Sulfated polysaccharide directs therapeutic angiogenesis via endogenous VEGF secretion of macrophages. Sci. Adv., 2021, 7 eabd8217

[36] Bishnoi, M. Chondroitin sulphate: a focus on osteoarthritis. Glycoconj. J.33, 693–705 (2016).

[37] Jackson RL, Busch SJ, Cardin AD. Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiological Rev., 1991, 71: 481-539

[38] Extracellular Sugar-Based Biopolymers Matrices. vol. 12 (Springer International Publishing, Cham, 2019).

[39] Guerrini Met al.. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat. Biotechnol., 2008, 26: 669-675

[40] Doncel-Pérez, E. Synthesis, physicochemical characterization and biological evaluation of chitosan sulfate as heparan sulfate mimics. Carbohydr. Poly.191, 225–233 (2018).

[41] Zhou Het al.. Enhanced bioactivity of bone morphogenetic protein-2 with low dose of 2-N, 6-O-sulfated chitosan in vitro and in vivo. Biomaterials, 2009, 30: 1715-1724

[42] Ji Let al.. 492-N, 6-O sulfated chitosan evokes periosteal stem cells for bone regeneration. Bioact. Mater., 2024, 34: 282-297

[43] Bhimraj Aet al.. Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19 (April 2020). Clin. Infect. Dis., 2024, 78: e83-e102

[44] Romeo, S. G. Endothelial proteolytic activity and interaction with non-resorbing osteoclasts mediate bone elongation. Nat. Cell Biol.21, 430–441 (2019).

[45] Tikhonova ANet al.. 54The bone marrow microenvironment at single-cell resolution. Nature, 2019, 569: 222-228

Funding

National Natural Science Foundation of China (National Science Foundation of China)(T2288102)

RIGHTS & PERMISSIONS

The Author(s)